Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
Rhea-AI Summary
Dyne Therapeutics (Nasdaq:DYN) has priced an upsized underwritten public offering of 18,300,000 shares of common stock at $20.50 per share, for expected gross proceeds of approximately $375.15 million before fees and expenses. All shares are being sold by Dyne.
The offering is expected to close on or about July 23, 2026, subject to customary conditions. Dyne has granted underwriters a 30-day option to purchase up to an additional 2,745,000 shares. Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital, Raymond James and Jones are managing the transaction.
Positive
- Upsized equity raise with expected gross proceeds of approximately $375.15 million
- Underwriters granted 30-day option for up to 2.745 million additional shares
- Offering expected to close by July 23, 2026, providing near-term capital inflow
Negative
- Issuance of 18.3 million new shares, plus potential 2.745 million more, may dilute existing shareholders
News Explained
If it closes, Dyne gets gross financing while new shares reduce existing holders’ percentage ownership; underwriting costs mean cash received will be lower.
The priced offering is not yet closed: if it completes, Dyne receives the gross proceeds from issuing new shares, while existing holders’ percentage ownership falls.
As an underwritten offering, investment banks buy the securities from Dyne and resell them; underwriting discounts, commissions, and expenses reduce net proceeds below the disclosed gross amount.
The Form S-3 provides registration capacity, but the priced offering is the specific sale; the registration filing itself did not sell shares.
Using Dyne’s operating cash use for the quarter ended
The company says it will file a final prospectus supplement, which states the offering’s final terms; closing is expected on or about
Sources and calculations
- Dyne Therapeutics pricing announcement (2026-07-21)
- Dilution definition (undated)
- Underwritten offering definition (undated)
- Form S-3 purpose (undated)
- Prospectus supplement purpose (undated)
- Dyne Therapeutics first-quarter fundamentals (2026Q1)
- Offering gross vs quarterly operating cash outflow, in days of cash use $375,000,000 / ($144,922,000 / 90) = [object Object]
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $753,102,000 / ($144,922,000 / 90) = [object Object]
News Market Reaction – DYN
In the Jul 22 session, DYN declined 2.60%, reflecting a moderate negative market reaction. Argus tracked a peak move of +6.1% during that session. Argus tracked a trough of -3.4% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. Trading volume was very high at 3.0x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 11 | Upsized offering | Negative | -0.8% | Closing of upsized common-stock offering with underwriters exercising the additional-share option |
| Dec 09 | Upsized offering | Negative | +6.8% | Pricing of $350 million common-stock offering with additional-share option |
| Dec 08 | Proposed offering | Negative | -16.9% | Commencement of $300 million common-stock offering with additional underwriter option |
| Jul 02 | Public offering | Negative | -2.0% | Completion of $230 million common-stock offering including full option exercise |
| Jun 30 | Public offering | Negative | -8.8% | Pricing of $200 million common-stock offering with additional-share option |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The tag-specific record showed predominantly negative reactions to Dyne offering announcements, with an average move of -4.35%.
Key Terms
underwritten public offering financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an upsized underwritten public offering of 18,300,000 shares of its common stock at a public offering price of
Morgan Stanley, Jefferies and Evercore ISI are acting as joint book-running managers for the offering. LifeSci Capital and Raymond James are also acting as joint book-running managers for the offering. Jones is acting as lead manager for the offering.
The offering is being made pursuant to a shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (“SEC”) on March 5, 2024 and became automatically effective upon filing. This offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and may be obtained for free by visiting the SEC’s website at www.sec.gov. A final prospectus supplement relating to the offering will be filed with the SEC. When available, copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at prospectus@morganstanley.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com; LifeSci Capital LLC, Attention: LifeSci Capital LLC, 1700 Broadway, 40th Floor, New York, NY 10019, or by email at legalnotices@lifescicapital.com; or Raymond James & Associates, Inc., at 880 Carillon Parkway, St. Petersburg, Florida 33716, Attention: Equity Syndicate, by calling toll-free at 1-800-248-8863, or emailing at prospectus@raymondjames.com.
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Dyne Therapeutics
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements relating to the anticipated closing date of the public offering, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including the risks and uncertainties related to the satisfaction of customary closing conditions for the public offering and other factors discussed in the “Risk Factors” section of the preliminary prospectus supplement filed with the SEC on July 21, 2026, as well as the risks and uncertainties identified in Dyne’s filings with the SEC, including Dyne’s most recent Form 10-Q and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne’s views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne’s views as of any date subsequent to the date of this press release.
Contacts:
Investors
Mia Tobias
ir@dyne-tx.com
781-317-0353
Media
Stacy Nartker
snartker@dyne-tx.com
781-317-1938
